UPK2 and urinary bladder carcinoma: The anti-tumor efficacy of bladder-cancer-specific OAds: Ad5/F11p-PSCA-UPII-E1A (Cao et al., 2017), Ad/PSCAF/UPII/E1A (Wang et al., 2014b), and KD01 (Guo et al., 2025), was tested using bladder cancer cell lines as monotherapy or in combination with cisplatin.